BioSpace News Archive

Recce Pharmaceuticals Ltd is pleased to report an Independent Safety Committee data review of 10 healthy human subjects intravenously dosed in the Phase I intravenous clinical trial of RECCE® 327, demonstrating a good safety and tolerability profile – unanimously recommending cohort four to commence.

Kala Pharmaceuticals, Inc. announced that UnitedHealthcare, one of the largest commercial health care plans in the United States, covering approximately 13 million lives, has added EYSUVIS 0.25% as a covered brand on its commercial formularies effective March 2022.

INOVIO announced that Dr. J. Joseph Kim, President and CEO, will participate in a fireside chat and 1x1 investor meetings at Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2021.

Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, announced that a new abstract showcasing XTMAB-16’s potential effect on sarcoidosis granuloma formation will be presented at the upcoming American Thoracic Society 2022 International Conference being held in San Francisco, CA from May 13-18, 2022.

Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing.

PhaseBio Pharmaceuticals, Inc oday announced the completion of the bentracimab drug substance and drug product Process Performance Qualification (PPQ) campaign.

Aytu BioPharma, Inc. announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu BioPharma, will participate in a fireside chat during the 34th Annual Roth Conference on Tuesday, March 15, 2022 at 2:00 p.m. PT.

The global personal mobility devices market will attain the valuation of US$ 18 Bn by 2027 end, states a new study published by Transparency Market Research.

Patient monitoring accessories refer to those devices that are utilized independently or it works with patient monitoring medical devices so as to offer timely and efficacious treatment.

According to the research authors at Transparency Market Research, the global orthobiologics market was evaluated at US$ 4.8 billion in the year of 2017 and the industry is set to mark the evaluation of whopping US$ 7.9 billion by the end of the forecast period in 2026.